{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T14:28:33Z","timestamp":1794234513469,"version":"4.9.0"},"reference-count":41,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T00:00:00Z","timestamp":1767830400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Neurol."],"DOI":"10.3389\/fneur.2025.1712202","type":"journal-article","created":{"date-parts":[[2026,1,8]],"date-time":"2026-01-08T05:11:59Z","timestamp":1767849119000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":2,"title":["Plasma exchange following immunoglobulins for Guillain-Barr\u00e9-Syndrome: a persisting problematic practice?"],"prefix":"10.3389","volume":"16","author":[{"given":"Guglielmo","family":"Lucchese","sequence":"first","affiliation":[{"name":"Department of Neurology, University Medicine Greifswald","place":["Greifswald, Germany"]},{"name":"Department of Experimental Medicine, University of Salento","place":["Lecce, Italy"]},{"name":"Neurology Unit, \u201cVito Fazzi\u201d Hospital","place":["Lecce, Italy"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,1,8]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3646","DOI":"10.1111\/ene.16073","article-title":"European Academy of Neurology\/Peripheral Nerve Society guideline on diagnosis and treatment of Guillain-Barr\u00e9 syndrome","volume":"30","author":"van Doorn","year":"2023","journal-title":"Eur J Neurol."},{"key":"B2","doi-asserted-by":"publisher","first-page":"671","DOI":"10.1038\/s41582-019-0250-9","article-title":"Diagnosis and management of Guillain-Barr\u00e9 syndrome in ten steps","volume":"15","author":"Leonhard","year":"2019","journal-title":"Nat Rev Neurol."},{"key":"B3","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/jca.22043","article-title":"Guidelines on the use of therapeutic apheresis in clinical practice - evidence-based approach from the writing committee of the American Society for Apheresis: the Ninth special issue","volume":"38","author":"Connelly-Smith","year":"2023","journal-title":"J Clin Apher."},{"key":"B4","doi-asserted-by":"publisher","first-page":"1214","DOI":"10.1016\/S0140-6736(21)00517-1","article-title":"Guillain-Barr\u00e9 syndrome","volume":"397","author":"Shahrizaila","year":"2021","journal-title":"Lancet."},{"key":"B5","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1016\/j.tracli.2024.11.005","article-title":"Potential advantage of therapeutic plasma exchange over intravenous immunoglobulin in children with axonal variant of Guillain-Barr\u00e9 syndrome: a report of six paediatric cases","volume":"32","author":"Deb","year":"2025","journal-title":"Transfus Clin Biol."},{"key":"B6","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1159\/000505964","article-title":"Child with Guillain-Barr\u00e9 syndrome responding to plasmapheresis: a case report","volume":"3","author":"Al Hamdani","year":"2020","journal-title":"Case Rep Acute Med."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1192","DOI":"10.1002\/mus.28265","article-title":"Intravenous immunoglobulin and plasma exchange prescribing patterns for Guillain-Barre Syndrome in the United States-2001 to 2018","volume":"70","author":"Stino","year":"2024","journal-title":"Muscle Nerve."},{"key":"B8","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1002\/ana.410340206","article-title":"Serum antibodies to GM1, GD1b, peripheral nerve myelin, and Campylobacter jejuni in patients with Guillain-Barr\u00e9 syndrome and controls: correlation and prognosis","volume":"34","author":"Vriesendorp","year":"1993","journal-title":"Ann Neurol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"168","DOI":"10.1002\/1531-8249(199902)45:2<168::aid-ana6>3.0.co;2-6","article-title":"Anti-GD1a antibody is associated with axonal but not demyelinating forms of Guillain-Barr\u00e9 syndrome","volume":"45","author":"Ho","year":"1999","journal-title":"Ann Neurol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"55","DOI":"10.1016\/j.jns.2013.11.016","article-title":"Clinical features in Guillain-Barr\u00e9 syndrome with anti-Gal-C antibody","volume":"337","author":"Samukawa","year":"2014","journal-title":"J Neurol Sci."},{"key":"B11","doi-asserted-by":"publisher","first-page":"86","DOI":"10.1186\/s43161-024-00258-8","article-title":"Autoimmune mechanisms in Guillain-Barr\u00e9 syndrome subtypes: a systematic review","volume":"29","author":"Oshomoji","year":"2024","journal-title":"Bull Fac Phys Ther."},{"key":"B12","doi-asserted-by":"publisher","first-page":"7288","DOI":"10.3390\/ijms24087288","article-title":"Immune-mediated neuropathies: pathophysiology and management","volume":"24","author":"Shastri","year":"2023","journal-title":"Int J Mol Sciences."},{"key":"B13","doi-asserted-by":"publisher","first-page":"41","DOI":"10.1016\/S0022-510X(02)00022-9","article-title":"Detection of antiganglioside antibodies in Guillain-Barr'e syndrome and its variants by the agglutination assay","volume":"196","author":"Alaedini","year":"2002","journal-title":"J Neurol Sci."},{"key":"B14","doi-asserted-by":"publisher","first-page":"160","DOI":"10.1038\/s41586-023-06916-6","article-title":"Autoreactive T cells target peripheral nerves in Guillain\u2013Barr\u00e9 syndrome","volume":"626","author":"S\u00faken\u00edkov\u00e1","year":"2024","journal-title":"Nature."},{"key":"B15","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1002\/ana.410440210","article-title":"IgG anti-GM1 antibody is associated with reversible conduction failure and axonal degeneration in Guillain-Barre syndrome","volume":"44","author":"Kuwabara","year":"1998","journal-title":"Ann Neurol."},{"key":"B16","doi-asserted-by":"publisher","first-page":"fcac306","DOI":"10.1093\/braincomms\/fcac306","article-title":"Complement inhibition prevents glial nodal membrane injury in a GM1 antibody-mediated mouse model","volume":"4","author":"Campbell","year":"2022","journal-title":"Brain Commun"},{"key":"B17","doi-asserted-by":"publisher","first-page":"469","DOI":"10.1038\/nrneurol.2014.121","article-title":"Guillain-Barr\u00e9 syndrome: pathogenesis, diagnosis, treatment and prognosis","volume":"10","author":"van den Berg","year":"2014","journal-title":"Nat Rev Neurol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1186\/s40478-016-0291-x","article-title":"C1q-targeted inhibition of the classical complement pathway prevents injury in a novel mouse model of acute motor axonal neuropathy","volume":"4","author":"McGonigal","year":"2016","journal-title":"Acta Neuropathol Commun."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1007\/s12028-024-01968-6","article-title":"The self-confirmatory history of plasmapheresis and IVIG","author":"Wijdicks","year":"","journal-title":"Neurocrit Care"},{"key":"B20","doi-asserted-by":"publisher","first-page":"190","DOI":"10.1093\/ajcp\/aqx056","article-title":"Therapeutic plasma exchange and its impact on drug levels: an ACLPS critical review","volume":"148","author":"Cheng","year":"2017","journal-title":"Am J Clin Pathol."},{"key":"B21","volume-title":"Intravenous immunoglobulin (IVIG)","author":"Arumugham","year":"2025"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2222","DOI":"10.1007\/s13311-021-01117-3","article-title":"Novel immunological and therapeutic insights in Guillain-Barr\u00e9 syndrome and CIDP","volume":"18","author":"Querol","year":"2021","journal-title":"Neurotherapeutics."},{"key":"B23","doi-asserted-by":"publisher","first-page":"328","DOI":"10.3390\/biomedicines11020328","article-title":"Therapeutic plasma exchange in certain immune-mediated neurological disorders: focus on a novel nanomembrane-based technology","volume":"11","author":"Tonev","year":"2023","journal-title":"Biomedicines."},{"key":"B24","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1016\/S1474-4422(20)30494-4","article-title":"Second intravenous immunoglobulin dose in patients with Guillain-Barr\u00e9 syndrome with poor prognosis (SID-GBS): a double-blind, randomised, placebo-controlled trial","volume":"20","author":"Walgaard","year":"2021","journal-title":"Lancet Neurol"},{"key":"B25","doi-asserted-by":"publisher","first-page":"966","DOI":"10.1002\/acn3.52313","article-title":"If it does not help, it might hurt: Pharmacodynamics of a second IVIg course in Guillain-Barr\u00e9 syndrome","volume":"12","author":"van Tilburg","year":"2025","journal-title":"Ann Clin Transl Neurol"},{"key":"B26","doi-asserted-by":"publisher","first-page":"3071","DOI":"10.1111\/ene.15500","article-title":"Outcome of Guillain-Barr\u00e9 syndrome following intravenous immunoglobulin compared to natural course","volume":"29","author":"Kalita","year":"2022","journal-title":"Eur J Neurol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"5","DOI":"10.1016\/j.ejpn.2020.01.003","article-title":"Diagnosis and treatment of Guillain-Barr\u00e9 Syndrome in childhood and adolescence: an evidence- and consensus-based guideline","volume":"25","author":"Korinthenberg","year":"2020","journal-title":"Eur J Paediatr Neurol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e000907","DOI":"10.1136\/bmjno-2024-000907","article-title":"Immunoglobulin unresponsive Guillain-Barr\u00e9 syndrome: rinse or repeat? A systematic review","volume":"7","author":"Roe","year":"2025","journal-title":"BMJ Neurol Open."},{"key":"B29","doi-asserted-by":"publisher","first-page":"4","DOI":"10.1097\/CND.0b013e318182b5ce","article-title":"Immunotherapy for Guillain-Barre syndrome in the US hospitals","volume":"10","author":"Alshekhlee","year":"2008","journal-title":"J Clin Neuromuscul Dis."},{"key":"B30","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1212\/01.wnl.0000167549.09664.b8","article-title":"Distinguishing acute-onset CIDP from Guillain-Barr\u00e9 syndrome with treatment related fluctuations","volume":"65","author":"Ruts","year":"2005","journal-title":"Neurology."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1680","DOI":"10.1212\/WNL.0b013e3181e07d14","article-title":"Distinguishing acute-onset CIDP from fluctuating Guillain-Barre syndrome: a prospective study","volume":"74","author":"Ruts","year":"2010","journal-title":"Neurology"},{"key":"B32","doi-asserted-by":"publisher","first-page":"119","DOI":"10.1016\/j.jocn.2020.11.013","article-title":"Guillain-Barr\u00e9 syndrome as a parainfectious manifestation of SARS-CoV-2 infection: a case series","volume":"83","author":"Abolmaali","year":"2021","journal-title":"J Clin Neurosci."},{"key":"B33","doi-asserted-by":"publisher","first-page":"577605","DOI":"10.1016\/j.jneuroim.2021.577605","article-title":"A case series of parainfectious Guillain-Barr\u00e9 syndrome linked to influenza A (H1N1) virus infection","volume":"357","author":"Grisanti","year":"2021","journal-title":"J Neuroimmunol."},{"key":"B34","doi-asserted-by":"publisher","first-page":"837","DOI":"10.1093\/cid\/cir074","article-title":"Guillain-Barr\u00e9 syndrome following primary cytomegalovirus infection: a prospective cohort study","volume":"52","author":"Orlikowski","year":"2011","journal-title":"Clin Infect Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"102993","DOI":"10.1016\/j.transci.2020.102993","article-title":"Potential of therapeutic plasmapheresis in treatment of COVID-19 patients: immunopathogenesis and coagulopathy","volume":"59","author":"Balagholi","year":"2020","journal-title":"Transfus Apher Sci."},{"key":"B36","doi-asserted-by":"publisher","first-page":"363","DOI":"10.1186\/s13054-020-03070-7","article-title":"First do no harm-beware the risk of therapeutic plasma exchange in severe COVID-19","author":"Stahl","year":"2020","journal-title":"Crit Care"},{"key":"B37","doi-asserted-by":"publisher","first-page":"987231","DOI":"10.3389\/fimmu.2022.987231","article-title":"Polyvalent human immunoglobulin for infectious diseases: Potential to circumvent antimicrobial resistance","volume":"13","author":"Pedraza-S\u00e1nchez","year":"2023","journal-title":"Front Immunol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1097\/CND.0000000000000256","article-title":"Rapid recovery with plasma exchange in acute motor axonal neuropathy with reversible conduction failure","volume":"21","author":"Burford","year":"2019","journal-title":"J Clin Neuromuscul Dis"},{"key":"B39","doi-asserted-by":"publisher","first-page":"4448","DOI":"10.1093\/brain\/awaf234","article-title":"Plasma periaxin is a biomarker of peripheral nerve demyelination","volume":"148","author":"Bellanti","year":"2025","journal-title":"Brain."},{"key":"B40","doi-asserted-by":"publisher","DOI":"10.1212\/WNL.0000000000212033","article-title":"Efficacy and safety of targeted immunotherapy with ANX005 in treating Guillain-Barr\u00e9 syndrome: a phase 3 multicenter study (PL5","author":"Kroon","year":"2025","journal-title":"Neurology"},{"key":"B41","unstructured":"Meglio\n              M\n            \n          \n          Positive Phase 2 Analyses Highlight Therapeutic Potential of Imlifidase in Guillain-Barr\u00e9 Syndrome"}],"container-title":["Frontiers in Neurology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1712202\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,9]],"date-time":"2026-11-09T14:17:09Z","timestamp":1794233829000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fneur.2025.1712202\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,8]]},"references-count":41,"alternative-id":["10.3389\/fneur.2025.1712202"],"URL":"https:\/\/doi.org\/10.3389\/fneur.2025.1712202","relation":{},"ISSN":["1664-2295"],"issn-type":[{"value":"1664-2295","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,8]]},"article-number":"1712202"}}